Won S. Kim

Won S. Kim

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 413 publications

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

Phase 1 Trial with Soquelitinib, a Selective ITK Inhibitor for Treatment of Relapsed/Refractory T Cell Lymphomas.

Journal: Blood
Published: April 30, 2026

Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study.

Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study.

Journal: British journal of haematology
Published: April 08, 2026

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

Journal: The Lancet. Haematology
Published: March 31, 2026

Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion.

Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion.

Journal: Leukemia & lymphoma
Published: March 17, 2026

Clinical heterogeneity of primary cutaneous γδ T-cell lymphoma: a 20-year single-institution experience.

Clinical heterogeneity of primary cutaneous γδ T-cell lymphoma: a 20-year single-institution experience.

Journal: Blood research
Published: March 16, 2026

Extranodal natural killer/T-cell lymphoma: From fatal to curable.

Extranodal natural killer/T-cell lymphoma: From fatal to curable.

Journal: CA: a cancer journal for clinicians
Published: March 04, 2026

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Journal: Blood advances
Published: January 16, 2026

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Journal: Blood advances
Published: January 16, 2026

Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.

Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.

Journal: International journal of clinical oncology
Published: January 06, 2026

Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01).

Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR-T) for relapsed/refractory large B-cell lymphoma (CRC01-01).

Journal: Blood
Published: January 05, 2026

Haematopoietic stem cell transplantation in hepatosplenic T-cell lymphoma: a retrospective analysis of the EBMT Lymphoma Working Party.

Haematopoietic stem cell transplantation in hepatosplenic T-cell lymphoma: a retrospective analysis of the EBMT Lymphoma Working Party.

Journal: The Lancet. Haematology
Published: December 28, 2025

Long-term outcomes of 40 Gy CCRT with weekly cisplatin and systemic chemotherapy in limited-stage ENKTL.

Long-term outcomes of 40 Gy CCRT with weekly cisplatin and systemic chemotherapy in limited-stage ENKTL.

Journal: Blood advances
Published: November 18, 2025
Showing 1-12 of 413

Last Updated: 09/26/2026